Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

Phase 3

Recruiting

• Conditions: Ovary Neoplasms; Ovarian Cancer; Ovarian Carcinoma
• Interventions: Drug: HIPEC

• Registration Number: NCT03842982
• Lead Sponsor: Centre Oscar Lambret

Brief Summary

This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care (PDS or IDS) or standard care alone.

Detailed Description

The primary objective of this study is to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC treatment combined with standard care (PDS or IDS) or standard care alone (PDS or IDS alone).

Secondary objectives of the study include:

* Evaluating the efficacy of HIPEC in terms of overall survival (OS) in combination with standard of care

* Evaluating the morbidity associated with HIPEC.

* Evaluating the trade-off between efficacy and morbidity using the Q-TWiST approach.

* Evaluating the impact of HIPEC in terms of quality of life.

Exploratory objectives (optional) include:

* Evaluating the impact of HIPEC on the count of residual viable cells (evaluated by flow cytometry) in abdominal drainage fluids for patients recruited in Centre Oscar Lambret only.

* Constituting a biobank (tumoral samples and blood samples) for future translational researches

Study Timeline

• Study First Submitted: 2019-02-13
• Study First Submitted QC: 2019-02-14
• Study First Posted: 2019-02-15
• Study Start: 2019-04-01
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-03
• Last Update Posted: 2024-06-04
• Primary Completion: 2027-08-01
• Study Completion: 2028-08-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 362

Inclusion Criteria

Pre-eligibility criteria to be checked before surgery for pre-registration

1. Age ≥18 years and ≤ 76 years

2. Histologically proven primary epithelial ovarian carcinoma or fallopian tube carcinoma or peritoneal carcinoma (including serous papillary adenocarcinoma, clear-cell carcinoma, mucinous adenocarcinoma and endometrioid carcinoma)

3. Pre-therapeutic FIGO (International Federation of Gynecology and Obstetrics) stage III

4. Patient eligible for

   1. Primary Debulking Surgery (PDS) with planned adjuvant chemotherapy +/- bevacizumab or other targeted therapy
   2. Or Interval Debulking Surgery (IDS) after neo-adjuvant chemotherapy +/- bevacizumab or other targeted therapy, with or without planned adjuvant chemotherapy +/- bevacizumab or other targeted therapy. In case of neo-adjuvant chemotherapy, surgery should be performed in a time interval of 3 to 5 weeks in case of chemotherapy without bevacizumab, and in a time interval of 4 to 6 weeks if chemotherapy is combined with bevacizumab. The patient remains eligible for the study if surgery is delayed beyond the recommended time interval.

5. WHO (World Health Organization Performance Status) ≤ 2

6. Physical status score ASA (American Society of Anesthesiologists) ≤ 2

7. Adequate bone marrow and renal function, as evidenced by the following tests performed within 7 days prior to surgery:

   • Absolute Neutrophil Count (ANC) ≥1,500/mm3
   • Platelets ≥100,000/mm3
   • Aspartate aminotransferase (ALT)/ Alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN) (≤5.0 × ULN in case of liver metastases)
   • Total bilirubin ≤1.5 × ULN (except in case of Gilbert's disease)
   • Creatinine clearance ≥ 60 mL/ min

8. Negative serum pregnancy test within 7 days prior to surgery for women of childbearing potential. For non-menopausal women, if no hysterectomy is planned, willing to accept the use of an effective contraceptive regimen during the treatment period and at least 6 months after the end of treatment (surgery or adjuvant chemotherapy)

9. Absence of contraindication to receive the products used in this study (cisplatin and products used in neo-adjuvant/ adjuvant chemotherapy) according to the most recent SmPC (Summary of Product Characteristics) of these products

10. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up

11. Signed written informed consent

12. Patient covered by the French or Belgian "Social Security" regime Criteria to be checked per-operatively for confirmation of enrolment and randomization

13. Residual disease after surgery (cytoreduction score CC) CC-0 (no macroscopic residue) or CC-1 (residue < 2.5 mm)

14. Per-operative hemorrhage < 2.5 L

15. Strictly less than 3 digestive resections performed during surgery

16. Diuresis maintained during surgery, without oliguria or anuria (per-operatory diuresis ≥ 0,5 mL/ kg/ h)

Exclusion Criteria

1. Benign disease, borderline disease, non epithelial ovarian carcinoma or carcinosarcoma
2. Cirrhosis
3. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
4. Auditory impairment
5. Dehydration or intercurrent disease that contraindicates hyperhydration (including cardio-respiratory disease)
6. Other uncontrolled intercurrent disease including, but not limited to: diabetes; hypertension; symptomatic congestive heart or pulmonary failure; renal, hepatic or severe gastrointestinal (associated with diarrhea) chronic disease
7. Any unresolved NCI-CTCAE Grade ≥ 2 toxicity from previous anticancer therapy (excluding alopecia)
8. Concomitant treatment with prophylactic phenytoin
9. Receipt of live attenuated vaccine, including yellow fever vaccine, within 30 days prior to inclusion (and, if patient is enrolled, up to 30 days after the last administration of study treatment)
10. Pregnant or breastfeeding woman
11. Psychiatric illness or social situation that would limit compliance with study requirement, substantially increase the risk of side effects, or compromise the ability of the patient to give written informed consent
12. Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)
13. Person under guardianship

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A (PDS or IDS + HIPEC)	HIPEC	Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy (standard care) + HIPEC (hyperthermic intraperitoneal chemotherapy) Patients in this experimental arm will receive surgery (either PDS or IDS) and Neo and/or Adjuvant chemotherapy (CT) (as per standard care) combined with HIPEC. Patients undergoing PDS will also be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery). Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.

Primary Outcome Measures

Name	Time	Method
Disease-free Survival (DFS)	From randomization to first progression, relapse or death from any cause, whichever came first, assessed up to 5 years. (Follow-up up to 5 years)	The DFS will be measured to assess the efficacy of the combination treatment of surgery and HIPEC or standard care alone.

Secondary Outcome Measures

Name	Time	Method
Overall survival	From randomization to first progression, relapse or death from any cause , whichever came first, assessed up to 5 years..	The overall survival will be measured to assess the efficacy of HIPEC in combination with standard care.
Adverse events (AE)	Covers the whole treatment duration from Randomization up to the end of treatment (surgery or CT) plus 30 days.	The adverse events (AE) are collected to evaluate the impact of HIPEC on the safety and on the feasibility of adjuvant treatment (if any) is planned after surgery.
Quality of life of the patient (QLQOV28)	Up to 2 years after the end of treatment (every 3 month)	European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Ovarian Cancer Module (QLQ-OV28) will be used to measure the quality of life of the patients.
Q-TWiST	Over the 5 year surveillance period	Q-Twist (Quality-adjusted time without symptoms of disease or toxicity) will be calculated from the survival tile (OS and DFS) and AE (adverse events) data.
Quality of life of the patient (QLQC30)	Up to 2 years after the end of treatment (every 3 month)	European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Score 30 (QLQ-C30) will be used to measure the quality of life of the patients.

Trial Locations

Locations (16)

Institut de Cancérologie de l'Ouest; 🇫🇷 Saint-Herblain, France

Centre François Baclesse; 🇫🇷 Caen, France

Institut Paoli Calmettes; 🇫🇷 Marseille, France

ICM-Val d'Aurelle; 🇫🇷 Montpellier, France

Hôpital Européen Georges Pompidou; 🇫🇷 Paris, France

Institut Gustave Roussy; 🇫🇷 Villejuif, France

Cliniques universitaires St-Luc, Institut Roi Albert II; 🇧🇪 Bruxelles, Belgium

Institut de Cancérologie de Lorraine; 🇫🇷 Vandœuvre-lès-Nancy, France

Institut Bergonié; 🇫🇷 Bordeaux, France

Centre Oscar Lambret; 🇫🇷 Lille, France

Hôpital Jeanne de Flandre; 🇫🇷 Lille, France

Centre Jean Perrin; 🇫🇷 Clermont-Ferrand, France

Centre Henri Becquerel; 🇫🇷 Rouen, France

Centre Hospitalier Lyon Sud; 🇫🇷 Pierre-Bénite, France

Clinique Mathilde; 🇫🇷 Rouen, France

Hôpital de Hautepierre; 🇫🇷 Strasbourg, France